Aprea Therapeutics (NASDAQ:APRE) Announces Quarterly Earnings Results

Aprea Therapeutics (NASDAQ:APRE) announced its quarterly earnings results on Wednesday. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01, FiscalAI reports. Aprea Therapeutics had a negative return on equity of 96.33% and a negative net margin of 4,405.59%.

Aprea Therapeutics Trading Down 2.2%

APRE traded down $0.02 during midday trading on Wednesday, hitting $0.88. 240,995 shares of the company were exchanged, compared to its average volume of 1,650,138. The company’s 50 day simple moving average is $0.82 and its 200 day simple moving average is $0.92. The firm has a market capitalization of $10.89 million, a price-to-earnings ratio of -0.44 and a beta of 1.48. Aprea Therapeutics has a 1-year low of $0.55 and a 1-year high of $2.22.

Institutional Trading of Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Jane Street Group LLC acquired a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned approximately 0.67% of Aprea Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 34.19% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on APRE. Weiss Ratings restated a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Monday, April 20th. HC Wainwright reduced their target price on Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Oppenheimer started coverage on shares of Aprea Therapeutics in a report on Thursday, May 7th. They issued an “outperform” rating and a $5.00 price target for the company. Zacks Research upgraded Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, February 16th. Finally, Wedbush reissued an “outperform” rating and issued a $7.00 price objective on shares of Aprea Therapeutics in a report on Tuesday, March 31st. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Aprea Therapeutics currently has an average rating of “Hold” and an average price target of $4.40.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.